Imvax
Philadelphia
About Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs. Its product, IGV-001, is an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the patient’s immune system as a defense mechanism. The company was incorporated in 2015 by David W. Andrews, Craig Hooper, Arthur W. Howe, and Peter B. Corr in Philadelphia, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $253.7M
- Last round: Series Unknown (Jan 2025)
- Website: imvax.com
- Phone: 215-485-0071
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/imvax-16454 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.